Jounce’s Cin­derel­la sto­ry now in­cludes a $102M IPO chap­ter

Every up-and-com­ing biotech in the in­dus­try likes to dream about do­ing that one big, trans­for­ma­tion­al deal that brings the spot­light and some rock star mar­ket ap­peal. And Jounce pulled one off last sum­mer, get­ting a rich­ly front-end­ed $2.6 bil­lion part­ner­ship with Cel­gene that helped them stand out from the im­muno-on­col­o­gy crowd — not so easy to do these days.

On Thurs­day, Cam­bridge, MA-based Jounce Ther­a­peu­tics com­plet­ed the sec­ond chap­ter of its Cin­derel­la sto­ry, break­ing past the range and rais­ing $102 mil­lion – well above its ini­tial $75 mil­lion mark­er – from an IPO. The biotech sold 6.36 mil­lion shares at $16 a share and will trade as JNCE. The un­der­writ­ers have an op­tion on about a mil­lion more shares.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.